Kamada Ltd Company Profile (NASDAQ:KMDA)

About Kamada Ltd (NASDAQ:KMDA)

Kamada Ltd logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KMDA
  • CUSIP: N/A
  • Web: www.kamada.com
  • Market Cap: $256.69 million
  • Outstanding Shares: 36,154,000
Average Prices:
  • 50 Day Moving Avg: $7.08
  • 200 Day Moving Avg: $6.44
  • 52 Week Range: $3.60 - $7.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 21.52
  • P/E Growth: -57.92
Sales & Book Value:
  • Annual Revenue: $74.35 million
  • Price / Sales: 3.45
  • Book Value: $1.75 per share
  • Price / Book: 4.06
  • EBIDTA: ($3,660,000.00)
  • Net Margins: -8.69%
  • Return on Equity: -9.77%
  • Return on Assets: -6.74%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 2.83%
  • Quick Ratio: 1.89%
  • Average Volume: 5,147 shs.
  • Beta: 1.02
  • Short Ratio: 1.35

Frequently Asked Questions for Kamada Ltd (NASDAQ:KMDA)

What is Kamada Ltd's stock symbol?

Kamada Ltd trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada Ltd's earnings last quarter?

Kamada Ltd (NASDAQ:KMDA) posted its earnings results on Tuesday, May, 16th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.08. The business had revenue of $11.65 million for the quarter, compared to analysts' expectations of $20.82 million. Kamada Ltd had a negative net margin of 8.69% and a negative return on equity of 9.77%. View Kamada Ltd's Earnings History.

Where is Kamada Ltd's stock going? Where will Kamada Ltd's stock price be in 2017?

2 brokerages have issued 12 month price targets for Kamada Ltd's stock. Their predictions range from $9.00 to $10.00. On average, they expect Kamada Ltd's stock price to reach $9.50 in the next twelve months. View Analyst Ratings for Kamada Ltd.

Are investors shorting Kamada Ltd?

Kamada Ltd saw a drop in short interest in the month of April. As of April 28th, there was short interest totalling 7,626 shares, a drop of 9.0% from the April 13th total of 8,382 shares. Based on an average trading volume of 3,768 shares, the days-to-cover ratio is currently 2.0 days.

Who are some of Kamada Ltd's key competitors?

Who owns Kamada Ltd stock?

Kamada Ltd's stock is owned by a number of of retail and institutional investors. Top institutional investors include Paulson & CO. Inc. (2.01%), Vanguard Group Inc. (1.21%), Renaissance Technologies LLC (0.73%), Acadian Asset Management LLC (0.23%), Analyst IMS Investment Management Services Ltd. (0.11%) and Edmond DE Rothschild Holding S.A. (0.10%). View Institutional Ownership Trends for Kamada Ltd.

Who bought Kamada Ltd stock? Who is buying Kamada Ltd stock?

Kamada Ltd's stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., Edmond DE Rothschild Holding S.A. and Geode Capital Management LLC. View Insider Buying and Selling for Kamada Ltd.

How do I buy Kamada Ltd stock?

Shares of Kamada Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kamada Ltd stock cost?

One share of Kamada Ltd stock can currently be purchased for approximately $7.10.

Analyst Ratings

Consensus Ratings for Kamada Ltd (NASDAQ:KMDA) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.50 (33.80% upside)

Analysts' Ratings History for Kamada Ltd (NASDAQ:KMDA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/17/2017Jefferies Group LLCReiterated RatingBuy$9.00HighView Rating Details
2/7/2017HC WainwrightSet Price TargetBuy$10.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Kamada Ltd (NASDAQ:KMDA)
Earnings by Quarter for Kamada Ltd (NASDAQ:KMDA)
Earnings History by Quarter for Kamada Ltd (NASDAQ:KMDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/20173/31/2017($0.03)($0.11)$20.82 million$11.65 millionViewN/AView Earnings Details
2/6/201712/31/2016($0.04)($0.05)$27.74 million$24.26 millionViewListenView Earnings Details
11/10/20169/30/2016($0.04)($0.03)$20.32 million$19.37 millionViewN/AView Earnings Details
8/2/2016Q216($0.04)($0.04)$18.50 million$19.10 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.06)($0.06)$15.10 million$14.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05$24.53 million$25.79 millionViewN/AView Earnings Details
11/12/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Kamada Ltd (NASDAQ:KMDA)
2017 EPS Consensus Estimate: $0.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.00$0.00$0.00
Q2 20171$0.10$0.10$0.10
Q3 20171$0.03$0.03$0.03
Q4 20171$0.06$0.06$0.06
(Data provided by Zacks Investment Research)


Dividend History for Kamada Ltd (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kamada Ltd (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com


Headline Trends for Kamada Ltd (NASDAQ:KMDA)
Latest Headlines for Kamada Ltd (NASDAQ:KMDA)
finance.yahoo.com logoKamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
finance.yahoo.com - May 24 at 11:14 AM
americanbankingnews.com logoKamada Ltd (KMDA) to Post Q2 2017 Earnings of $0.10 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 19 at 7:16 AM
americanbankingnews.com logoShort Interest in Kamada Ltd (KMDA) Decreases By 9.0%
www.americanbankingnews.com - May 18 at 4:22 PM
americanbankingnews.com logoKamada Ltd (KMDA) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - May 18 at 12:30 PM
americanbankingnews.com logoFY2017 EPS Estimates for Kamada Ltd Reduced by Jefferies Group (KMDA)
www.americanbankingnews.com - May 18 at 10:38 AM
finance.yahoo.com logoKamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss
finance.yahoo.com - May 17 at 6:10 PM
americanbankingnews.com logoKamada Ltd (KMDA) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - May 17 at 11:34 AM
americanbankingnews.com logoKamada Ltd (KMDA) Issues Earnings Results
www.americanbankingnews.com - May 17 at 10:03 AM
finance.yahoo.com logoKamada Reports 2017 First Quarter Financial Results
finance.yahoo.com - May 16 at 10:49 AM
finance.yahoo.com logoKamada reports 1Q loss
finance.yahoo.com - May 16 at 10:49 AM
finance.yahoo.com logoInvestor Network: Kamada Ltd to Host Earnings Call
finance.yahoo.com - May 16 at 10:49 AM
americanbankingnews.com logo Analysts Anticipate Kamada Ltd (KMDA) Will Post Quarterly Sales of $20.82 Million
www.americanbankingnews.com - May 14 at 9:24 AM
finance.yahoo.com logoKamada to Host First Quarter 2017 Financial Results Conference Call on May 16
finance.yahoo.com - May 8 at 9:26 AM
americanbankingnews.com logoKamada (KMDA) Receives News Sentiment Rating of 0.35
www.americanbankingnews.com - May 3 at 1:00 AM
americanbankingnews.com logoKamada (KMDA) Receiving Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 12:14 AM
americanbankingnews.com logoKamada (KMDA) Receives Media Impact Score of -0.12
www.americanbankingnews.com - April 24 at 1:38 PM
americanbankingnews.com logoKamada Ltd (KMDA) Expected to Announce Quarterly Sales of $20.82 Million
www.americanbankingnews.com - April 23 at 8:16 AM
americanbankingnews.com logoKamada (KMDA) Receiving Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 5:28 PM
americanbankingnews.com logoKamada (KMDA) Earns Media Impact Score of 0.40
www.americanbankingnews.com - April 13 at 3:16 PM
americanbankingnews.com logoKamada's (KMDA) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - April 12 at 3:53 PM
finance.yahoo.com logoKAMADA LTD Financials
finance.yahoo.com - March 7 at 5:56 PM
finance.yahoo.com logoKamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)
finance.yahoo.com - March 2 at 6:24 PM
streetinsider.com logoKamada (KMDA) to Collaborate with MGH on Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver ... - StreetInsider.com
www.streetinsider.com - February 22 at 6:22 PM
streetinsider.com logoKamada (KMDA) to Collaborate with MGH on Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
www.streetinsider.com - February 22 at 12:25 PM
us.rd.yahoo.com logoKamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
us.rd.yahoo.com - February 22 at 12:25 PM
us.rd.yahoo.com logo6:33 am Kamada announces a collaboration w/ Massachusetts General Hospital to conduct a study evaluating the potential benefit of its Liquid Alpha-1 Antitrypsin on liver preservation
us.rd.yahoo.com - February 22 at 12:25 PM
finance.yahoo.com logoKamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors
finance.yahoo.com - February 8 at 6:56 PM
globenewswire.com logoKamada Reports Financial Results for the Fourth Quarter and Full-Year 2016
globenewswire.com - February 6 at 10:21 AM
finance.yahoo.com logoKamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6
finance.yahoo.com - February 1 at 6:58 PM
globenewswire.com logoKamada Announces Positive Scientific Advice Response from the European ...
globenewswire.com - January 23 at 10:37 AM
streetinsider.com logoKamada (KMDA) Announces Positive Scientific Advice Response from CHMP on G1-AAT IV for aGvHD
www.streetinsider.com - January 23 at 10:37 AM
finance.yahoo.com logo6:30 am Kamada announces positive scientific advice response from the EMA focused on Alpha-1 Antitrypsin IV for treatment of acute graft-versus-host disease; co is in the process of reviewing CHMP guidance
finance.yahoo.com - January 23 at 10:37 AM
finance.yahoo.com logoKamada Announces Positive Scientific Advice Response from the European Medicines Agency Focused on Alpha-1 Antitrypsin IV for Treatment of Acute Graft-Versus-Host Disease
finance.yahoo.com - January 23 at 10:37 AM
streetinsider.com logoKamada (KMDA) Enters Recombinant Human Alpha 1 Antitrypsin Development Agreement
www.streetinsider.com - November 15 at 6:25 PM
finance.yahoo.com logoKamada Announces Collaboration Agreement with Yissum for Development of a Recombinant Human Alpha 1 Antitrypsin
finance.yahoo.com - November 15 at 9:28 AM
finance.yahoo.com logoCan Agilent Technologies (A) Pull a Surprise in Q4 Earnings?
finance.yahoo.com - November 14 at 9:54 AM
streetinsider.com logoKamada (KMDA), Kedrion Biopharma Announce FDA Acceptance of IgG Therapy BLA
www.streetinsider.com - November 8 at 8:47 AM
seekingalpha.com logoFDA accepts Kamada's marketing application for rabies IgG therapy; action date August 29, 2017
seekingalpha.com - November 7 at 9:40 AM
finance.yahoo.com logoKedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment
finance.yahoo.com - November 7 at 9:40 AM
finance.yahoo.com logoKamada to Host Third Quarter Financial Results Conference Call on November 10, 2016 at 8:30 am Eastern Time
finance.yahoo.com - November 3 at 9:34 AM
finance.yahoo.com logoKamada (KMDA) Extends Partnership with Shire for Glassia
finance.yahoo.com - October 10 at 10:30 AM
nasdaq.com logoExtended Agreement May Expand to $288 Million of Revenue in 2017 to 2020
www.nasdaq.com - October 6 at 5:42 PM
seekingalpha.com logoKamada and Shire extend Glassia supply agreement through 2020
seekingalpha.com - October 6 at 5:42 PM
streetinsider.com logoKamada (KMDA), Shire (SHPG) Extend GLASSIA Supply and Distribution Agreement
www.streetinsider.com - October 6 at 5:42 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Kamada
finance.yahoo.com - September 12 at 5:38 PM
finance.yahoo.com logoKamada to Present a Corporate Overview at the Rodman & Renshaw 18th Annual Investment Conference
finance.yahoo.com - September 9 at 10:35 AM
benzinga.com logoH.C. Wainwright Talks Kamada's Recent Phase 2 Results
www.benzinga.com - September 1 at 5:42 PM
seekingalpha.com logoMarketing application filed in U.S. for Kamada's post-exposure rabies therapy; launch planned in 2017
seekingalpha.com - September 1 at 8:54 AM
streetinsider.com logoKamada (KMDA): Phase II Trial Adds Support For Inhaled AAT Therapy - Jefferies
www.streetinsider.com - August 31 at 10:40 AM
nasdaq.com logoKamada's Phase 2 Trial Of Alpha-1 Antitrypsin Therapy Meets Primary Endpoint
www.nasdaq.com - August 30 at 9:06 AM



Kamada Ltd (KMDA) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff